NeuroMetrix Story

Are NeuroMetrix (NASDAQ:NURO) institutional investors starting to hold back?
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as NeuroMetrix. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for NeuroMetrix

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of NeuroMetrix's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of NeuroMetrix in the context of predictive analytics.

Hype Prediction Details

Intrinsic Valuation Details

Naive Forecast Details

Bollinger Band Projection (param) Details

Please note, it is not enough to conduct a financial or market analysis of a single entity such as NeuroMetrix. Your research has to be compared to or analyzed against NeuroMetrix's peers to derive any actionable benefits. When done correctly, NeuroMetrix's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in NeuroMetrix.

How important is NeuroMetrix's Liquidity

NeuroMetrix financial leverage refers to using borrowed capital as a funding source to finance NeuroMetrix ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. NeuroMetrix financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between NeuroMetrix's total debt and its cash.

How NeuroMetrix utilizes its cash?

To perform a cash flow analysis of NeuroMetrix, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash NeuroMetrix is receiving and how much cash it distributes out in a given period. The NeuroMetrix cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. NeuroMetrix Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (4.49 Million)

Acquisition by Van Avermaete David of 5000 shares of NeuroMetrix subject to Rule 16b-3

Legal trades by NeuroMetrix insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:

NeuroMetrix insider trading alert for grant of stock option (right to buy common stock) by Van Avermaete David, the corporate stakeholder, on 15th of January 2021. This event was filed by Neurometrix Inc with SEC on 2021-01-15. Statement of changes in beneficial ownership - SEC Form 4 [view details]

Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper look at NeuroMetrix

About Contributor